These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 9805032

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The quandary of Creutzfeldt-Jakob disease.
    Larke B.
    CMAJ; 1998 Oct 06; 159(7):789-92. PubMed ID: 9805025
    [No Abstract] [Full Text] [Related]

  • 3. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: theoretical risk for real people.
    King SM, Watson H, Heurter H, Ricketts M, Elsaadany S.
    CMAJ; 1998 Oct 06; 159(7):771-4. PubMed ID: 9805022
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives.
    Vamvakas EC.
    J Clin Apher; 1999 Oct 06; 14(3):135-43. PubMed ID: 10540369
    [Abstract] [Full Text] [Related]

  • 6. Creutzfeldt-Jakob disease: the problem of recipient notification.
    DuVal G.
    J Law Med Ethics; 1997 Oct 06; 25(1):34-41, 3. PubMed ID: 11066473
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of being placed at risk of Creutzfeldt-Jakob disease: a qualitative study of blood donors to variant CJD cases and patients potentially surgically exposed to CJD.
    Elam G, Oakley K, Connor N, Hewitt P, Ward HJ, Zaman SM, Chow Y, Marteau TM.
    Neuroepidemiology; 2011 Oct 06; 36(4):274-81. PubMed ID: 21757956
    [Abstract] [Full Text] [Related]

  • 9. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML, Ludlam CA.
    Br J Haematol; 2009 Jan 06; 144(1):14-23. PubMed ID: 18950452
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Recipients of blood or blood products "at vCJD risk".
    Bird SM.
    BMJ; 2004 Jan 17; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Creutzfeldt-Jakob disease latest unknown in struggle to restore faith in blood supply.
    Vaughan P.
    CMAJ; 1996 Sep 01; 155(5):565-8. PubMed ID: 8804263
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study.
    Dorsey K, Zou S, Schonberger LB, Sullivan M, Kessler D, Notari E, Fang CT, Dodd RY.
    Transfusion; 2009 May 01; 49(5):977-84. PubMed ID: 19170987
    [Abstract] [Full Text] [Related]

  • 18. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G.
    Haemophilia; 2006 Mar 01; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [Abstract] [Full Text] [Related]

  • 19. Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.
    Menache D, O'Malley JP.
    Biologicals; 1996 Sep 01; 24(3):277-83. PubMed ID: 8978926
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.